The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results-Reference-Cited by-同舟云学术

The effect of denosumab in breast cancer patients receiving adjuvant aromatase inhibitors: 36-month results

Published:2020-09-05 Issue:2 Volume:39 Page:224-229
ISSN:0914-8779
Container-title:Journal of Bone and Mineral Metabolism
language:en
Short-container-title:J Bone Miner Metab

Author:

Ouchi Yoshimi,Nakatsukasa Katsuhiko,Sakaguchi Koichi,Morita Midori,Koyama Hiroshi,Matsuda Takayuki,Kato Makoto,Konishi Eiichi,Ono Hisako,Taguchi Tetsuya^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Orthopedics and Sports Medicine,General Medicine,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s00774-020-01138-6.pdf

Reference35 articles.

1. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE (2006) Effect of an aromatase inhibitor on bmd and bone turnover markers: 2 year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 21:1215–1223

2. Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC (2007) Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8:119–127

3. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271

4. Gonnelli S, Cadirni A, Caffarelli C, Petrioli R, Montagnani A, Franci MB, Lucani B, Francini G, Nuti R (2007) Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane. Bone 40:205–210

5. Hadji P, Ziller M, Kieback DG, Dornoff W, Tessen HW, Menschik T, Kuck J, Melchert F, Hasenburg A (2009) Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12 month, prospective, randomised substudy. Ann Oncol 20:1203–1209

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Denosumab effect on bone mineral density and urinary-NTX in breast cancer patients receiving aromatase inhibitors;Journal of Bone and Mineral Metabolism;2023-05-29

2. Postmenopausal osteoporosis: risk evaluation and treatment options;Minerva Obstetrics and Gynecology;2021-12

3. Consolidation of Tumorous Mandibular Ramus Defect During Denosumab Treatment for Rapidly Progressive Metastatic Breast Cancer;Anticancer Research;2021-09-30

4. Adjuvant endocrine therapy effects on bone mineral density and microstructure in women with breast cancer;Journal of Bone and Mineral Metabolism;2021-06-30